These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17958410)

  • 21. E-novo: an automated workflow for efficient structure-based lead optimization.
    Pearce BC; Langley DR; Kang J; Huang H; Kulkarni A
    J Chem Inf Model; 2009 Jul; 49(7):1797-809. PubMed ID: 19552372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multimode ligand binding in receptor site modeling: implementation in CoMFA.
    Lukacova V; Balaz S
    J Chem Inf Comput Sci; 2003; 43(6):2093-105. PubMed ID: 14632461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GPCR structure-based virtual screening approach for CB2 antagonist search.
    Chen JZ; Wang J; Xie XQ
    J Chem Inf Model; 2007; 47(4):1626-37. PubMed ID: 17580929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of ligand-based and structure-based 3D-QSAR approaches: a case study on (aryl-)bridged 2-aminobenzonitriles inhibiting HIV-1 reverse transcriptase.
    Sciabola S; Carosati E; Baroni M; Mannhold R
    J Med Chem; 2005 Jun; 48(11):3756-67. PubMed ID: 15916427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Raptor: combining dual-shell representation, induced-fit simulation, and hydrophobicity scoring in receptor modeling: application toward the simulation of structurally diverse ligand sets.
    Lill MA; Vedani A; Dobler M
    J Med Chem; 2004 Dec; 47(25):6174-86. PubMed ID: 15566288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Homology-modelling protein-ligand interactions: allowing for ligand-induced conformational change.
    Dalton JA; Jackson RM
    J Mol Biol; 2010 Jun; 399(4):645-61. PubMed ID: 20434455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein.
    Gohlke H; Klebe G
    J Med Chem; 2002 Sep; 45(19):4153-70. PubMed ID: 12213058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular modeling of protein function regions.
    DeWeese-Scott C; Moult J
    Proteins; 2004 Jun; 55(4):942-61. PubMed ID: 15146492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consensus scoring with feature selection for structure-based virtual screening.
    Teramoto R; Fukunishi H
    J Chem Inf Model; 2008 Feb; 48(2):288-95. PubMed ID: 18229906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Scoring ligand similarity in structure-based virtual screening.
    Zavodszky MI; Rohatgi A; Van Voorst JR; Yan H; Kuhn LA
    J Mol Recognit; 2009; 22(4):280-92. PubMed ID: 19235177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Binding response: a descriptor for selecting ligand binding site on protein surfaces.
    Zhong S; MacKerell AD
    J Chem Inf Model; 2007; 47(6):2303-15. PubMed ID: 17900106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of consensus scoring strategies for evaluating computational models of protein-ligand complexes.
    Oda A; Tsuchida K; Takakura T; Yamaotsu N; Hirono S
    J Chem Inf Model; 2006; 46(1):380-91. PubMed ID: 16426072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Receptor-based QSAR studies of non-peptide human oxytocin receptor antagonists.
    Jójárt B; Márki A
    J Mol Graph Model; 2007 Jan; 25(5):711-20. PubMed ID: 16857401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative assessment of scoring functions on a diverse test set.
    Cheng T; Li X; Li Y; Liu Z; Wang R
    J Chem Inf Model; 2009 Apr; 49(4):1079-93. PubMed ID: 19358517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Homology modeling of the serotonin 5-HT1A receptor using automated docking of bioactive compounds with defined geometry.
    Nowak M; Kołaczkowski M; Pawłowski M; Bojarski AJ
    J Med Chem; 2006 Jan; 49(1):205-14. PubMed ID: 16392805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin.
    Baum B; Muley L; Heine A; Smolinski M; Hangauer D; Klebe G
    J Mol Biol; 2009 Aug; 391(3):552-64. PubMed ID: 19520086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
    Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
    Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-dimensional QSAR of HPPD inhibitors, PSA inhibitors, and anxiolytic agents: effect of tautomerism on the CoMFA models.
    Zou JW; Luo CC; Zhang HX; Liu HC; Jiang YJ; Yu QS
    J Mol Graph Model; 2007 Sep; 26(2):494-504. PubMed ID: 17418602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enzyme binding selectivity prediction: alpha-thrombin vs trypsin inhibition.
    Mlinsek G; Novic M; Kotnik M; Solmajer T
    J Chem Inf Comput Sci; 2004; 44(5):1872-82. PubMed ID: 15446847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening.
    Cavasotto CN; Orry AJ; Murgolo NJ; Czarniecki MF; Kocsi SA; Hawes BE; O'Neill KA; Hine H; Burton MS; Voigt JH; Abagyan RA; Bayne ML; Monsma FJ
    J Med Chem; 2008 Feb; 51(3):581-8. PubMed ID: 18198821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.